Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

HCV combination therapy

a combination therapy and viral technology, applied in the field of hcv combination therapy, can solve the problems of combination therapy not always effective, decompensated liver disease and/or hepatocellular carcinoma, cirrhosis of the liver, etc., and achieve the effect of reducing viral-rna and ameliorating ribavirin-related hemolysis

Inactive Publication Date: 2005-02-01
MERCK SHARP & DOHME CORP
View PDF5 Cites 56 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0008]The present invention provides methods for treating susceptible viral infections, especially hepatitis C viral infections, which comprises administering to said patient a therapeutically effecti

Problems solved by technology

It can eventually result in cirrhosis of the liver, decompensated liver disease and / or hepatocellular carcinoma.
However this combination therapy is not always effective due to side effects associated with ribavirin such as ribavirin-related hemolysis as measured by reduced hemoglobin concentrations.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0015]The present invention provides methods for treating susceptible viral infections, especially hepatitis C viral infections.

[0016]The term “susceptible viral infections” as used herein means viral infections caused by a wide range of RNA and DNA viruses, including, but not limited to, the families of viruses such as flaviruses-including the genus flavirus, pestivirus of which Kunjin virus is a member, and hepavirus of which hepatitis C virus is a member, and arbovirus of which the West Nile virus is a member-orthomyxoviruses, paramyxoviruses, arenaviruses, bunyaviruses, herpes viruses, adenoviruses, poxviruses, and retroviruses.

[0017]Typical suitable “susceptible viral infections” include influenza A and B viral infections; parainfluenza viral infections, respiratory syncytial virus(“RSV”) infections such as RSV bronchiolitis and RSV pneumonia especially such RSV infections in children and infants as well as RSV pneumonia in patients with preexisting cardiopulmonary disease, mea...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Timeaaaaaaaaaa
Timeaaaaaaaaaa
Dimensionless propertyaaaaaaaaaa
Login to View More

Abstract

Methods of treating patients having susceptible viral infections, especially chronic hepatitis C infection by administering to said patient a therapeutically effective amount of a combination therapy of interferon-alfa and ribavirin for a time sufficient to lower HCV-RNA in association with a therapeutically effective amount of an antioxidant for a time sufficient to ameliorate ribavirin-related hemolysis are disclosed.

Description

[0002]This application claims benefit of U.S. Provisional Patent Application No. 60,129,991 filed Apr. 19, 1999.BACKGROUND OF THE INVENTION[0003]The present invention relates to methods of treating patients having susceptible viral infections, especially chronic hepatitis C infections by administering to said patient a therapeutically effective amount of a combination therapy of interferon-alfa and ribavirin for a time sufficient to lower HCV-RNA in association with a therapeutically effective amount of an antioxidant for a time sufficient to ameliorate ribavirin-related hemolysis.[0004]A chronic hepatitis C viral infection is a particularly insidious and slow-progressing viral disease having a significant impact on the quality of life. It can eventually result in cirrhosis of the liver, decompensated liver disease and / or hepatocellular carcinoma.[0005]Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients, is disclosed by Reichard et al.(The...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/70A61K38/21A61K31/355A61K31/34A61K31/352
CPCA61K31/34A61K31/355A61K31/70A61K38/212A61K2300/00
Inventor BRASS, CLIFFORD A.GLUE, PAUL W.PIKEN, EDWARD
Owner MERCK SHARP & DOHME CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com